Clinical Characteristics of Pigmentary Glaucoma and Efficacy Analysis of Ab-interno 120° Trabeculotomy
Recruiting · NCT07713056 · Observational (researchers observe without assigning treatment)
View the official record on ClinicalTrials.gov →Interventions studied
Ab-interno 120° Trabeculotomy
What this trial is about
This study aims to investigate the clinical characteristics of pigmentary glaucoma and evaluate the efficacy and safety of ab-interno 120° trabeculotomy during the 6-month postoperative follow-up period.
Who can take part
Age range
16 Years to 80 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Meet the clinical diagnostic criteria for pigmentary glaucoma, with typical signs of pigment dispersion syndrome, extensive trabecular meshwork pigmentation, pathological intraocular pressure elevation, glaucomatous optic nerve damage, and characteristic visual field defects;
- Underwent primary isolated ab-interno 120° trabeculotomy as the initial surgical treatment;
- Have complete preoperative and postoperative examination data, including slit-lamp biomicroscopy, gonioscopy, intraocular pressure, visual field, and OCT RNFL measurements;
- Able to complete regular follow-up for at least 6 months postoperatively.
Exclusion criteria
- Patients with exfoliation syndrome, exfoliative glaucoma, or other types of primary or secondary glaucoma;
- Patients with a history of ocular trauma, intraocular surgery, uveitis, severe retinopathy, or other ocular diseases affecting intraocular pressure and visual function assessment;
- Patients who underwent combined procedures such as concurrent cataract surgery or other anti-glaucoma surgeries during the operation;
- Patients with severe systemic diseases, cognitive or psychiatric disorders that prevent cooperation with examinations and follow-up;
- Patients with missing key clinical or follow-up data that preclude efficacy and prognosis evaluation.
Where it is running
1 location listed.
- Zhongnan Hospital of Wuhan University - Wuhan, Hubei, China